IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale lowered its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 190,719 shares of the medical research company’s stock after selling 8,318 shares during the period. DekaBank Deutsche Girozentrale owned 0.10% of IQVIA worth $47,898,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. AdvisorNet Financial Inc lifted its stake in shares of IQVIA by 327.6% in the 4th quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after acquiring an additional 95 shares during the period. Rise Advisors LLC acquired a new stake in shares of IQVIA in the 1st quarter worth $31,000. Riverview Trust Co acquired a new stake in shares of IQVIA in the 1st quarter worth $32,000. Covestor Ltd lifted its stake in shares of IQVIA by 45.3% in the 1st quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock worth $39,000 after acquiring an additional 48 shares during the period. Finally, Security National Bank acquired a new stake in shares of IQVIA in the 4th quarter worth $41,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on IQV. Jefferies Financial Group cut shares of IQVIA from a “buy” rating to a “hold” rating and reduced their target price for the stock from $266.00 to $242.00 in a research note on Wednesday, July 24th. Robert W. Baird raised their price objective on shares of IQVIA from $235.00 to $251.00 and gave the company a “neutral” rating in a research note on Tuesday, July 23rd. Argus upgraded shares of IQVIA to a “strong-buy” rating in a research note on Wednesday. UBS Group raised their price objective on shares of IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Finally, StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Monday, July 15th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $262.40.

IQVIA Trading Down 2.6 %

Shares of NYSE IQV traded down $6.58 during midday trading on Friday, reaching $241.78. 1,141,380 shares of the stock were exchanged, compared to its average volume of 1,284,778. The company has a market capitalization of $44.08 billion, a P/E ratio of 33.03, a P/E/G ratio of 2.35 and a beta of 1.49. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. The stock has a 50 day moving average price of $221.77 and a 200-day moving average price of $230.37.

IQVIA (NYSE:IQV) last released its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The firm had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. During the same period in the previous year, the firm earned $2.22 earnings per share. IQVIA’s revenue was up 2.3% compared to the same quarter last year. Equities research analysts expect that IQVIA Holdings Inc. will post 10.21 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.